LivaNova (NASDAQ:LIVN) Upgraded by StockNews.com to “Buy”

LivaNova (NASDAQ:LIVN) was upgraded by investment analysts at StockNews.com from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Thursday.

Several other equities research analysts also recently commented on LIVN. Robert W. Baird boosted their target price on shares of LivaNova from $56.00 to $62.00 and gave the stock a “neutral” rating in a research report on Thursday, February 22nd. Needham & Company LLC reissued a “buy” rating and set a $72.00 target price on shares of LivaNova in a research report on Wednesday, March 20th. Mizuho reissued a “buy” rating and set a $75.00 target price on shares of LivaNova in a research report on Wednesday, March 27th. Finally, Barclays upped their price objective on shares of LivaNova from $57.00 to $61.00 and gave the stock an “equal weight” rating in a research report on Monday, February 26th. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, LivaNova currently has a consensus rating of “Moderate Buy” and a consensus target price of $64.40.

LivaNova Trading Up 1.7 %

NASDAQ:LIVN opened at $55.94 on Thursday. The company has a current ratio of 2.95, a quick ratio of 2.51 and a debt-to-equity ratio of 0.44. The stock has a market capitalization of $3.02 billion, a price-to-earnings ratio of 174.82 and a beta of 0.89. The firm has a fifty day simple moving average of $53.92 and a two-hundred day simple moving average of $50.59. LivaNova has a 12 month low of $42.75 and a 12 month high of $59.86.

LivaNova (NASDAQ:LIVN) last posted its quarterly earnings results on Wednesday, February 21st. The company reported $0.87 EPS for the quarter, topping analysts’ consensus estimates of $0.77 by $0.10. The business had revenue of $310.10 million during the quarter, compared to analysts’ expectations of $287.65 million. LivaNova had a net margin of 1.53% and a return on equity of 12.23%. The business’s quarterly revenue was up 12.8% on a year-over-year basis. During the same period last year, the company posted $0.81 earnings per share. Analysts expect that LivaNova will post 3.01 EPS for the current fiscal year.

Institutional Investors Weigh In On LivaNova

Institutional investors have recently added to or reduced their stakes in the company. Headlands Technologies LLC bought a new position in shares of LivaNova during the 3rd quarter valued at approximately $72,000. Picton Mahoney Asset Management bought a new position in shares of LivaNova during the 3rd quarter valued at approximately $91,000. Vanguard Personalized Indexing Management LLC bought a new position in shares of LivaNova during the 3rd quarter valued at approximately $217,000. AlphaMark Advisors LLC bought a new position in shares of LivaNova during the 3rd quarter valued at approximately $244,000. Finally, Jump Financial LLC bought a new position in shares of LivaNova during the 3rd quarter valued at approximately $273,000. 97.64% of the stock is owned by institutional investors.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.